Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive September 1, 2013 William Looney	High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets.
Pharmaceutical Executive March 12, 2012 William Looney	Novartis: LEADing in Emerging Markets With growth as its guiding light, Novartis has big plans for the emerging markets. CEO Joe Jimenez tells us what it will take the company to best the competition.
Pharmaceutical Executive July 1, 2009	The Pharmerging Future A guide to grabbing growth in seven "pharmerging" markets.
Pharmaceutical Executive November 1, 2008	No Ordinary Joe It's been a year since consumer marketing master Joe Jimenez took over the top spot at Novartis Pharma. How's he faring?
Pharmaceutical Executive April 1, 2006 Christensen, McLaughlin & Wunker	The Road to Nowhere? More effective drugs? Another dead end. But patients open their wallets when a "good enough" drug gets better.
Managed Care March 2007 Martin Sipkoff	Managing Cancer Treatment Begins Before Diagnosis Health plans are increasingly involved in promoting the lifestyle changes that help their members avoid cancer, and are increasingly involved in clinical trials if prevention fails.
Pharmaceutical Executive February 1, 2013 William Looney	In Cancer, Process Drives Progress Today's most important public health story is the advance in our understanding of the biology of cancer.
BusinessWeek April 18, 2005 Manjeet Kripalani	India: Bigger Pharma Tougher patent protection laws are spurring rapid growth in new drug research across India.
Pharmaceutical Executive August 1, 2013 Joseph Saba	New Rules for a New Africa Declining revenue growth in the United States and Europe have sent pharmaceutical companies in search of opportunities in the BRICs and other emerging economies. Now, companies are finally turning their attention to Africa.
Pharmaceutical Executive March 1, 2011 William Looney	Making Sense of Market Chaos Pharma can be an insular industry, with limited capacity to gaze beyond its own narrow frame of vision
Pharmaceutical Executive February 1, 2011 William Looney	Tracking the US Market: A Statistical Self-Portrait What are some of the essential characteristics of the US market? Statistics drawn from the 2011 Statistical Abstract of the US shed some light
Pharmaceutical Executive November 1, 2013 William Looney	Payers: Late for the Party? Pharm Exec's two key features this month illustrate the strategic contradiction facing today's industry.
Pharmaceutical Executive August 1, 2011 William Looney	Paying for Health -- The Right Way What Big Pharma fails to see is how engagement in health policy is the biggest of reputation builders
Pharmaceutical Executive February 1, 2006 Chandler & Chicco	Public Relations: Damage Control Unless pharma defines a compelling story, and defends it vigorously in the consumer marketplace, others will enter that vacuum and tell the story for it -- in far less flattering ways
Pharmaceutical Executive April 1, 2012	Leading from the South India's most prominent scientist sets a new agenda for pharma in emerging markets.
Pharmaceutical Executive January 21, 2014 Comer & Upton	Pharm Exec's Annual Industry Outlook 2014 For Big Pharma, the merits of strategic focus and operational discipline are more important than ever. It is time to be decisive; muddling through is so yesterday.
Pharmaceutical Executive July 3, 2007	Thought Leader: Connected Markets, Rob Dhoble It used to be that pharma companies had one marketing strategy for the US and other developed nations, a second strategy for emerging countries, and a third, mostly focused around access, for the developing world. But in a global environment, that doesn't work.
Pharmaceutical Executive August 1, 2011 Ben Comer	Is the 'Emerging Market' a Dated Concept? When it comes to the emerging markets, executing a few key elements of success are more important than ever.
Pharmaceutical Executive January 1, 2006 Patrick Clinton	From the Editor: A Wild 25 This has been an amazing quarter century for the pharmaceuticals industry, and it has brought us to a point at which the next quarter century can only be more of the same
Pharmaceutical Executive June 1, 2006 Patrick Clinton	From the Editor: Forecast -- and Fast The glory of the years to come will be in new science, new medicines, and new cures. But someone has to do the hard, scary work of guaranteeing the survival of the businesses that bring new cures to patients.
Pharmaceutical Executive September 1, 2012 Robin Hertz	The Endless Treadmill of End-of-Life Care Bending the cost curve back to valuing the cycle of life.
Pharmaceutical Executive February 1, 2013 William Looney	Pathways to Progress Cancer is increasingly understood as a collection of rare and mostly treatable conditions rather than the impregnable, monolith portrayed in popular culture. Industry experts review current and pending efforts to turn great science into good practice.
The Motley Fool May 31, 2011 Brian Orelli	Profit From This Growing Drug Trend Cancer drugs press on.
AskMen.com Jacob Franek	Prostate Cancer Overview Everything you wanted to know and more about prostate cancer in this three-part prostate cancer guide.
BusinessWeek June 13, 2005 Catherine Arnst	Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins.
Pharmaceutical Executive April 1, 2014 William Looney	The Trials of Commerce Four commercial line executives serve as our jury of peers on what's in store for the future of pharma, and discuss the changing criteria for market success, from drugs to consumer products to vaccines.
Pharmaceutical Executive September 1, 2011 Don Creighton	Bridging the Hidden Hurdle in Cancer Cures Diagnostics can boast the efficacy of drug treatments, but delivering the promise depends on a predictable pathway to reimbursement.
BusinessWeek February 16, 2004 Catherine Arnst	Medicare vs. Cancer Patients Refusing to reimburse off-label treatment is far from the best way to cut costs.
Pharmaceutical Executive January 1, 2012 William Looney	Pharma 2012: Hard Times Before the Harvest 2012 will be a transition year for pharma, one of the most important in its history. The challenge is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap.
Chemistry World July 15, 2008 Hepeng Jia	Testing Times for New Liver Drug AstraZeneca is set to start clinical trials of a liver cancer drug developed for Chinese patients.
Managed Care March 2007 Lola Butcher	Plans Put Greater Emphasis On Cancer Management Increasingly, health plans are rolling out services designed to help cancer patients and, before that, plan members at a high risk of cancer, to improve their health care and, in doing so, limit costs.
Pharmaceutical Executive July 1, 2013 Looney et al.	Pharm Exec's 2013 Emerging Pharma Leaders Meet the Emerging Pharma Leaders of 2013. These 15 trend setters represent the future of an industry that knows it must change: the question is how, and to what?
Pharmaceutical Executive July 1, 2013 William Looney	Talent, Terror, and the Turnaround We offer news on 15 new Emerging Pharma Leaders, business innovation, and terrorism threats to the pharmaceutical industry.
Science News May 13, 2000	Cancer Net CancerNet is a huge compendium of information on cancer assembled by the National Cancer Institute....
Pharmaceutical Executive October 1, 2010	When the Payer IS the Player As Medicare, Medicaid, and the nation's web of private payers gain market power, how can pharma stay ahead of the cost-containment curve?
American Journal of Nursing March 2006 Pamela J. Haylock	The Shifting Paradigm of Cancer Care: The Many Needs of Cancer Survivors Are Starting to Attract Attention The complexities of survivorship, and the growing population of survivors who share these challenges has led to an increase awareness of a need for survivorship research on the sequelae of cancer and cancer treatment.
Pharmaceutical Executive January 21, 2014 William Looney	Russia's Bet on Biopharma Can innovation trump ideology? Russia faces a stark choice in betting on the visible hand of government in promoting a "world class" biopharmaceutical sector
Pharmaceutical Executive December 1, 2010 Zhu Shen	China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda
Pharmaceutical Executive February 1, 2009 Patrick Clinton	Working Together No one who cares about global health can be happy with a system that only "eventually" delivers drugs and vaccines for the planet's neediest people.
Pharmaceutical Executive July 3, 2007	Harbingers of Change What to watch, and watch out for, in the bottom half of '07. The IMS Health Editorial Board identifies what it believes are the key events that will impact the global pharmaceutical market in the near future.
Pharmaceutical Executive August 1, 2011 William Looney	Innovation at Pfizer A Q and A with Kristin Peck, the drug maker's Executive Vice President, Worldwide Business Development and Innovation.
Managed Care January 2005 Sharon Baker	Breast Cancer Screening: Some Plans Do Better Than Others Some of the nation's best health plans are coming up with creative ways to encourage women to get mammograms.
Pharmaceutical Executive July 1, 2012 William Looney	The Learning Curve In a wake up call to this year's Emerging Leaders a group of St. Joseph's Business School Health Management alumni say time has no limit on surprises; change for pharma is here and it's good.
Pharmaceutical Executive April 1, 2011	How US Health Reform Is Hitting Canada Canada's Russell Williams, of Rx&D, talks about the impact of US health reform on his role as chief spokesman for the country's R&D industry.
Pharmaceutical Executive April 1, 2006 Joanna Breitstein	HBA Woman of the Year: Susan Desmond-Hellman There are people who hope cancer, one day, will become a manageable disease. Then there are those who know it. Meet Susan Desmond-Hellmann.
Pharmaceutical Executive June 1, 2014 Jill Wechsler	What Price Innovation? Payers, drug plans seek clear assessment of drug value to rationalize high drug prices.
Pharmaceutical Executive June 1, 2011	Emerging Pharma Leaders 2011 Meet 2011's Emerging Pharma Leaders. Can these 30 trendsetters build competitive scale from scarcity?
BusinessWeek January 30, 2006 Catherine Arnst	Going Broke To Stay Alive Rising prices for cancer treatments are making patients - and doctors - balk.
BusinessWeek August 26, 2010 Tom Randall	Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer.
Chemistry World May 21, 2009 Matt Wilkinson	Big Pharma set for generics boost Pharmaceutical firms have been rushing to ensure they minimize their losses by expanding their generics businesses and reach into emerging markets.